How BridgeBio Pharma stock has been trading

BridgeBio Pharma (BBIO) has drawn investor attention after a strong 1 year total return of 93.54%. This contrasts with weaker recent trading, with the stock down 6.2% over the past month and 13.79% year to date.

The recent 1 day and 1 month share price declines sit against a much stronger backdrop, with a 1 year total shareholder return of 93.54% and a 3 year total shareholder return above 3x. This pattern suggests recent momentum is fading in the short term even as longer term holders have seen substantial gains. This can reflect shifting views on BridgeBio Pharma's growth potential and risk profile rather than a clear change in fundamentals on its own.

If you are weighing BridgeBio Pharma against other opportunities in the sector, it can be helpful to see what else is moving and how. A practical next step is to scan for other healthcare stocks using AI as a growth driver, starting with 35 healthcare AI stocks.

With BridgeBio Pharma revenue at US$502.1m, a reported net loss of US$724.9m, and some measures pointing to a possible discount to estimated value, investors may be wondering whether this represents a buying opportunity or if potential future growth is already reflected in the current price.

Most Popular Narrative: 33.1% Undervalued

BridgeBio Pharma's most followed valuation narrative pegs fair value at about $100.89 per share, versus the last close of $67.45. This frames a sizable implied discount using a 7.37% discount rate and detailed long term forecasts.

The company's late-stage pipeline, with three Phase III readouts imminent across high unmet need rare disease indications, positions BridgeBio to leverage advancements in biotechnology for potential first-to-market and best-in-class therapies. This creates the opportunity for multiple revenue inflection points and margin improvement as the portfolio diversifies. Established commercial and patient support infrastructure, enabled by strong sales execution and white-glove access models, is expected to be redeployed for future launches. This may reduce incremental fixed costs per new product and support long-term operational leverage and net margin expansion.

Want to see how this late stage pipeline story translates into that fair value number? The narrative leans on rapid revenue compounding, a sharp margin swing, and a richer earnings multiple built into the 2029 outlook.

Result: Fair Value of $100.89 (UNDERVALUED)

However, this story can change quickly if Attruby underperforms expectations or if late stage trials and regulatory decisions for key pipeline drugs do not go as planned.

Another way to look at valuation

The narrative and analyst targets suggest that BridgeBio Pharma is trading at a 77.2% discount to an estimated fair value of $296.40 based on our DCF model. That is a large gap for any stock. The key question is how comfortable you are with the growth and margin assumptions that support this estimate.

Next Steps

Given the mix of optimism and concern running through this story, it makes sense to review the numbers yourself and decide where you stand, especially with 2 key rewards and 1 important warning sign.

Looking for more investment ideas?

If you stop at one stock, you might miss opportunities that fit your style even better, so keep widening the lens with a few focused stock lists.

• Target potential mispricings by scanning 51 high quality undervalued stocks that pair quality fundamentals with prices that look out of sync with the underlying business.
• Prioritise resilience first by checking 71 resilient stocks with low risk scores built around companies with lower risk profiles that may suit a steadier approach.
• Stay one step ahead of the crowd with the screener containing 23 high quality undiscovered gems that highlight underfollowed stocks backed by solid numbers.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.